Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an amendment with the Securities and Exchange Commission on March 6, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 3,404,256 shares of common stock by certain institutional investors. These shares are issuable upon the exercise of warrants that were part of a private placement and registered direct offering that occurred on January 30, 2024. The warrants have an exercise price of $1.05 per share, are currently exercisable, and will expire five and a half years from the date of issuance. Seelos Therapeutics will not receive any proceeds from the sale of shares by the institutional investors but may receive proceeds from any cash exercise of the warrants. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL'.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, filed an amendment with the Securities and Exchange Commission on March 6, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 3,404,256 shares of common stock by certain institutional investors. These shares are issuable upon the exercise of warrants that were part of a private placement and registered direct offering that occurred on January 30, 2024. The warrants have an exercise price of $1.05 per share, are currently exercisable, and will expire five and a half years from the date of issuance. Seelos Therapeutics will not receive any proceeds from the sale of shares by the institutional investors but may receive proceeds from any cash exercise of the warrants. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'SEEL'.